IP Library › Granted Patent US 12,209,107
Granted Patent B2
US 12,209,107 · App. 16/822,385 · Granted Jan 28, 2025

Process for preparing high puritiy allopregnanolone and intermediates thereof

Inventors: Ivano Messina (Valladolid, ES); Jesús Miguel Iglesias Retuerto (Valladolid, ES); Ana María Ares Sacristán (Valladolid, ES)
Assignee: CRYSTAL PHARMA, S.A.U.
C07J9/00C07J7/009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,107
App. No.
16/822,385
Granted
Jan 28, 2025
Kind
B2
Abstract

The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.

Claims (22)

1. A chromatography-free process for preparing allopregnanolone which comprises:

reacting isoallopregnanolone with a strong carboxylic acid having a pKa≤3 under suitable Mitsunobu conditions, thereby obtaining a 3-carboxylic ester of allopregnanolone;

precipitating the 3-carboxylic ester of allopregnanolone in a solvent system comprising water and an organic solvent;

purifying the precipitate of the 3-carboxylic ester of allopregnanolone by recrystallizing in a non-polar solvent; and

subjecting the purified 3-carboxylic ester of allopregnanolone to hydrolysis, thereby obtaining allopregnanolone.

2. The process according to claim 1 , wherein the hydrolysis occurs under (i) neutral conditions, (ii) mild basic conditions by treatment with a base whose conjugate acid has a pKa≤11, or (iii) energetic basic conditions by treatment with a base whose conjugate acid has a pKa≥12.

3. The process according to claim 1 , wherein the strong carboxylic acid is selected from the group consisting of mono-, di-, and trifluoroacetic acid, mono-, di-, and trichloroacetic acid, cyanoacetic acid, and ortho-nitrobenzoic- and dinitrobenzoic acid.

4. The process according to claim 1 , wherein the 3-carboxylic ester of allopregnanolone is precipitated in a solvent system comprising water and a water-soluble organic solvent.

5. The process according to claim 1 , wherein the 3-carboxylic ester of allopregnanolone is precipitated in a solvent system comprising water and a water-soluble organic solvent selected from 1,4-dioxane, acetone, acetonitrile, DMF, methanol, ethanol, isopropanol, and mixtures thereof,

and/or

the precipitate of the 3-carboxylic ester of allopregnanolone is recrystallized in a non-polar solvent selected from group consisting of hexane, cyclohexane, heptane, toluene, iPr 2 O, MeOtBu, and mixtures thereof.

6. The process according to claim 2 , wherein the 3-carboxylic ester of allopregnanolone is subjected to hydrolysis under neutral conditions with an alcohol without adding any acid or base.

7. The process according to claim 2 , wherein the 3-carboxylic ester of allopregnanolone is subjected to hydrolysis with a base whose conjugate acid has a pKa≤11.

8. The process according to claim 7 , wherein the base whose conjugate acid has a pKa≤11 is an alkali or alkaline earth carbonate or bicarbonate.

9. The process according to claim 2 , wherein the 3-carboxylic ester of allopregnanolone is subjected to hydrolysis with a base whose conjugate acid has a pKa≥12 for a time and at a temperature suitable to keep the level of 3α-hydroxy-5α,17α-pregnan-20-one in an amount of 0.5% or less.

10. The process according to claim 9 , wherein the base whose conjugate acid has a pKa≥12 is an alkali or alkaline earth C 1-6 alkoxide or hydroxide.

11. The process according to claim 9 , wherein the hydrolysis is carried out for not more than about 2 h and/or at a temperature of about 15-40° C.

12. The process according to claim 1 , wherein following precipitation and recrystallization, the allopregnanolone has a total content of 5α-pregn-2-en-20-one and 3α-hydroxy-5α,17α-pregnan-20-one of about 0.15% or below.

13. The process according to claim 2 , wherein the hydrolysis under energetic basic conditions is carried out for not more than about 2 h and/or at a temperature of about 15-40° C.

14. The process according to claim 1 , wherein the suitable Mitsunobu conditions comprise use of at least one phosphine, at least one azodicarboxylate, and optionally a tertiary amine additive, wherein the at least one phosphine is selected from the group consisting of triphenyl phosphine, dicyclohexylphenylphosphine, diethylphenylphosphine, tributylphosphine, diphenyl-2-pyridylphosphine, 4-(dimethylamino) phenyldiphenylphosphine, isopropyldiphenylphosphine, tri-tert-butylphosphine, tri-n-octylphosphine, tricyclohexylphosphine, polystyryldiphenylphosphine, and a mixture thereof, and wherein the at least one azodicarboxylate is selected from the group consisting of diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), di-t-butyl azodicarboxylate, 1,1′-(azocarbonyl) dipiperidine, dibenzyl azodicarboxylate, and a mixture thereof.

15. The process according to claim 1 , wherein the purified 3-carboxylic ester of allopregnanolone contains an amount of 5α-pregn-2-en-20-one of about 0.5% or less.

16. The process according to claim 5 , wherein the ratio of water to water-soluble organic solvent is about 0.2:1 to 1:0.2.

Assignments (4)
CHANGE OF NAME Recorded Nov 5, 2025
From: CRYSTAL PHARMA, S.A.U.
To: CURIA SPAIN, S.A.U.
Reel/Frame 073449/0630 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 054320 FRAME: 0125. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 17, 2020
From: BIONICE, S.L.U
To: CRYSTAL PHARMA, S.A.U.
Reel/Frame 054702/0748 →
MERGER Recorded Nov 10, 2020
From: BIONICE, S.L.U
To: CRYSTAL PHARMA, S.A.U.
Reel/Frame 054320/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2020
From: MESSINA, IVANO; IGLESIAS RETUERTO, JESUS MIGUEL; ARES SACRISTAN, ANA MARIA
To: BIONICE, S.L.U.
Reel/Frame 052699/0389 →
Priority Claims (1)
EP 19382193 · Mar 19, 2019 · regional
Continuity (1)
Related Publication 20200299323A1 · Sep 24, 2020
References Cited (31)
US 4061661A · Wiechert et al. · 1977 [cited by applicant]
US 5232917A · Bolger et al. · 1993 [cited by applicant]
US 20180311258A1 · Robichaud et al. · 2018 [cited by applicant]
US 20190002492A1 · Mensah-Nyagan et al. · 2019 [cited by applicant]
US 20200087341A1 · Torregrossa · 2020 [cited by examiner]
CN 103396467 · 2013 [cited by examiner]
CN 103396467A1 · 2013 [cited by applicant]
WO 9303732A1 · 1993 [cited by applicant]
WO 2009108804A2 · 2009 [cited by applicant]
WO 2012127176A1 · 2012 [cited by applicant]
WO 2016164763A1 · 2016 [cited by applicant]
Varasi et al. (J. Org. Chem., 1987, 52(19), pp. 4235-4238). [cited by examiner]
Acidity of Alcohols, Libretexts <https://chem.libretexts.org/Bookshelves/Organic_Chemistry/Supplemental_Modules_(Organic_Chemistry)/Alcohols/Properties_of_Alcohols/Acidities_of_Alcohols#:˜: text=A>, pp. 1-2, downloaded … [cited by examiner]
15.09 Hydrolysis of Esters, Libretexts <https://chem.libretexts.org/Courses/Eastern_Mennonite_University/EMU%3A_Chemistry_for_the_Life_Sciences_(Cessna)/15%3A_Organic_Acids_and_Bases_and_Some_of_Their_Derivatives/15.09_… [cited by examiner]
One%20such%20reaction%20is%20hydrolysis,containing%20a%20strong%2Dacid%20catalyst>, pp. 1-3, downloaded Jan. 18, 2023. [cited by examiner]
Kapras, Vojětch, et al.; “Preparation of steriod sulfamates and their interaction with GABAA [cited by applicant]
Fukushima, David K., et al.; “Studies in Steroid Metabolism; XXV. Isolation and Characterization of New Urinary Steriods,” J. Biol. Chem., 1954, vol. 210, pp. 129-137. [cited by applicant]
Euw, Von J.V., et al.; “3 Alpha, 17 Alpha, 21-Trihydroxy-5 Alpha-pregnan-20-on und Subst. TR 1018,” Helv.Chim. Acta, 1962, vol. 45, pp. 224-232. [cited by applicant]
Hirschmann, H., et al,; “Chemical Interrelationships Between Some 20-Hydroxysteriods,” J. Biol. Chem., 1951, vol. 192, pp. 115-129. [cited by applicant]
Moffett, Robert Bruce, et al.; “17-Isopregnan-3(alpha)-ol-20-one,” JACS, 1944, vol. 66, pp. 2098-2100. [cited by applicant]
Soloway, A.H., et al.; “Differential Reduction of Steroid Ketones,” JACS, 1953, vol. 75, pp. 2356-2358. [cited by applicant]
Purdy, Robert H., et al.; Synthesis, Metabolism, and Pharmacological Activity of 3 alpha-Hydroxy Steriods Which Potentiate GABA-Receptor-Mediated Chloride Ion Uptake in Rat Cerebral Cortical Synaptoneurosomes, J. Med. C… [cited by applicant]
European Search Report, Sep. 18, 2019 for European Patent Application No. 19382193.1. [cited by applicant]
Mancera et al., Steroids, XLIII. A Ten Step Conversion of Progesterone to Cortisone. The Differential Reduction of Pregnane-3,20-diones with Sodium Borohydride, Journal of the American Chemical Society, Mar. 20, 1953, v… [cited by applicant]
Tsunoda et al., Mitsunobu Acylation of Sterically Congested Secondary Alcohols by N,N,N', N'-Tetramethylazodicarboxamide-Tributylphosphine Reagents, Tetrahedron Letters, 1995, vol. 36, No. 14, pp. 2529-2530. [cited by applicant]
Asahara et al., Solvent Handbook, Kodansha Ltd., pp. 47-51, (1985). [cited by applicant]
Ashizawa, Optimization of salt and crystal forms and crystallization techniques, Pharm Tech Japan, vol. 18, No. 10, pp. 81-96 (2002). [cited by applicant]
Dodge et al., Effect of the Acidic Component on the Mitsunobu Inversion of a Sterically Hindered Alcohol, The Journal of Organic Chemistry, vol. 59, No. 1, pp. 234-236 (1994). [cited by applicant]
Martin et al., Efficacious Modification of the Mitsunobu Reaction for Inversions of Sterically Hindered Secondary Alcohols, Tetrahedron Letters, vol. 32, No. 26, 3017-3020 (1991). [cited by applicant]
Saïah et al., The Use of Chloroacetic Acid in the Mitsunobu Reaction, Tetrahedron Letters, vol. 33, No. 30,4317-4320 (1992). [cited by applicant]
Tsunoda et al., Development of New Mitsunobu Reagents, Journal of Synthetic Organic Chemistry, Japan, vol. 55, No. 7, pp. 631-641 (1997). [cited by applicant]